1. Home
  2. GSIW vs INAB Comparison

GSIW vs INAB Comparison

Compare GSIW & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSIW

Garden Stage Limited

HOLD

Current Price

$0.15

Market Cap

28.6M

Sector

N/A

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.91

Market Cap

22.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSIW
INAB
Founded
2016
2016
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.6M
22.9M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
GSIW
INAB
Price
$0.15
$1.91
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$108.00
AVG Volume (30 Days)
536.0K
71.3K
Earning Date
01-01-0001
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,087,497.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
515.58
N/A
52 Week Low
$0.09
$1.17
52 Week High
$1.79
$12.53

Technical Indicators

Market Signals
Indicator
GSIW
INAB
Relative Strength Index (RSI) 49.42 44.08
Support Level $0.11 $1.85
Resistance Level $0.16 $2.07
Average True Range (ATR) 0.01 0.16
MACD -0.00 -0.03
Stochastic Oscillator 68.62 13.85

Price Performance

Historical Comparison
GSIW
INAB

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: